← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	NSTG 26 DELISTED NanoString Technologies, Inc. NSTG	85	+8	+10%	$214M
27	SIOX 27 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	81	+11	+16%	$323M
28	ATHX 28 DELISTED Athersys, Inc. Common Stock ATHX	78	+14	+22%	$32.8M
29	29 DELISTED Adverum Biotechnologies ADVM	77	-5	-6%	$49.8M
30	30 Atara Biotherapeutics ATRA $92.6M	74	+3	+4%	$493M
31	31 Lineage Cell Therapeutics LCTX $243M	74	+8	+12%	$99.9M
32	32 Invesco Biotechnology & Genome ETF PBE $431M	73	+2	+3%	$51M
33	33 Regenxbio RGNX $459M	69	+5	+8%	$147M
34	34 Editas Medicine EDIT $366M	68	+19	+39%	$550M
35	BLCM 35 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	67	-11	-14%	$229M
36	36 Rocket Pharmaceuticals RCKT $250M	66	+8	+14%	$147M
37	37 Intellia Therapeutics NTLA $1.63B	62	+62	–	$302M
38	38 uniQure QURE $1.51B	59	+2	+4%	$60M
39	39 Veracyte VCYT $3.66B	58	+3	+5%	$77.5M
40	40 Fortress Biotech FBIO $64.4M	52	+8	+18%	$21.8M
41	41 Vericel Corp VCEL $2.12B	52	+3	+6%	$24.5M
42	42 Arbutus Biopharma ABUS $840M	51	+2	+4%	$61.1M
43	43 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	51	+1	+2%	$9.56M
44	NVTA 44 DELISTED Invitae Corporation NVTA	49	+8	+20%	$159M
45	45 Voyager Therapeutics VYGR $127M	48	+5	+12%	$116M
46	ADAP 46 DELISTED Adaptimmune Therapeutics ADAP	47	-2	-4%	$260M
47	47 Fate Therapeutics FATE $231M	39	-7	-15%	$23.9M
48	48 Wave Life Sciences WVE $611M	39	+16	+70%	$294M
49	49 Cellectis CLLS $110M	38	-6	-14%	$184M
50	50 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	38	+6	+19%	$543M